Personal Profile

Ma Xiaoying, more than 20 years experience of clinical work in oncology, and is currently a member of the Specialized Committee on Medical Oncology, Chinese Anti-Cancer Association (CACA ) and member of Specialized Committee of Tumor Endoscopy. She specializes in chemotherapy, endocrine therapy, molecular targeted therapy and immunotherapy for various malignant tumors, including digestive tract tumors, breast cancer, lung cancer, gynecological tumors, genitour and genitourinary tumors, as well as the treatment of advanced and refractory tumors. also familiar with the minimally invasive treatment of various malignant tumors. especially for the treatment of advanced and refractory tumors with rich clinical experience. meanwhile she has published many academic thesis in professional journals.

Educational Background:

2009  Master of Medicine Degree

2015 Exchange Study at National University Hospital, Singapore

2017  Advance study in Oncology Department of Sun Yat-sen University Cancer Center

2019 Advance study in Endoscopy Department of Sun Yat-sen University Cancer Center

Medical Experience:

More than 20 years of clinical work in oncology, especially for the treatment of advanced and refractory tumors with rich clinical experience.

Academic achievements:

Combined with clinical practice, during her master's degree, Dr. Ma wrote academic thesis on tumor research, which were published in professional oncology journals and other journals, were highly recognized by experts in the field of medical oncology. Dr. Ma maintains a good habit of reading a lot of medical books and often participates in academic seminars, asking for advice and discussing with medical experts to continuously learn advanced medical technologies to supplement her medical knowledge.

Research techniques:

Minimally invasive targeted immunotherapy for solid tumors

Research Directions:

Oncology 

*Surgery, in addition to the appropriate chemotherapy and radiotherapy, are effective in treating early cancer, but certain patients in late stage of cancer may not be tolerate surgery well as they can be relatively weak. A combination of carefully planned minimally invasive therapy, chemotherapy or radiotherapy can effectively reduce the side effects and discomfort of treatment and may help patient get better efficacy.